REG - Trellus Health PLC - Posting of Annual Report & Accounts

Trellus HealthAnnouncement

25/05/2022 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220525:nRSY7651Ma&default-theme=true

RNS Number : 7651M  Trellus Health PLC  25 May 2022

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Posting of Annual Report & Accounts

and

Notice of Annual General Meeting

 

LONDON, UK. AND NEW YORK, U.S. (25 May 2022). Trellus Health plc (AIM: TRLS),
which is commercialising a scientifically validated, resilience-based,
connected health solution for chronic condition management, confirms that the
Annual Report and Accounts for the year ended 31 December 2021 ("2021 Annual
Report") and the Notice of the 2022 Annual General Meeting ("AGM") have now
been published on the Company's website here
(https://trellushealth.com/investors/) .

 

The 2021 Annual Report, the Notice of AGM and details for voting by
proxy will be posted to shareholders today, on 25 May 2022. Beneficial
shareholders who received Trellus shares from the distribution in specie by
EKF Diagnostics Holdings plc will receive details for voting by proxy in the
post.

 

The AGM is to be held at 2:00pm on 27 June 2022 at the Company's registered
offices, at Avon House, 19 Stanwell Road, Penarth, Cardiff, CF64 2EZ and will
consider the Resolutions set out in the Notice of AGM.

 

The Company is providing a facility for shareholders to listen in to the AGM
either online or telephonically (in a non-voting capacity) and there will be
an opportunity for shareholders to ask questions. In order to facilitate the
process, the Directors would request that shareholders register for the
meeting and submit questions in advance, before 2:00pm on 24 June 2022. To
register for dial-in details and to submit any questions please contact
Walbrook PR via email at trellus@walbrookpr.com or call +44 (0)20 7933 8780.

 

Proxy voting

Shareholders will not receive a hard copy form of proxy for the 2022 AGM in
the post. Instead, Shareholders will be able to vote electronically using the
link www.signalshares.com (http://www.signalshares.com/) . Proxy votes must
be received no later than 2:00pm on 23 June 2022.

 

Shareholders may request a hard copy form of proxy directly from the
Registrars, Link Group, on Tel: 0371 664 0300. Calls are charged at the
standard geographic rate and will vary by provider. Calls outside the United
Kingdom will be charged at the applicable international rate. Lines are open
between 09:00 - 17:30, Monday to Friday excluding public holidays in England
and Wales.

 

For further information please contact:

 

 Trellus Health plc                                       www.trellushealth.com (http://www.trellushealth.com)
 Monique Fayad, CEO                                       Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR Limited                                      Tel: 020 7933 8780 or trellus@walbrookpr.com (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen                                 Mob: 07980 541 893 / 07502 558 258

 

 

About Trellus Health plc (www.trellushealth.com)

 

Trellus Health (LSE: TRLS) is the first digital health company focused on the
intersection of chronic physical conditions and mental health. Trellus Health
integrates its proprietary resilience-based methodology with the technology,
tools and team to deliver a whole-person technology-enhanced experience that
results in relieving disease burden and promoting individual health behaviors
that enable thriving in the face of a chronic condition. Through its
TrellusElevate™ connected care platform and companion App, the company
addresses both clinical and behavioral health together, in context, to improve
outcomes and reduce healthcare costs for patients, employers, and the
healthcare system.

 

The Company is initially focused on Inflammatory bowel disease ("IBD"), which
includes the chronic incurable conditions of Crohn's Disease and ulcerative
colitis, but considers its approach to have potential utility and demand
across many chronic conditions, including Irritable Bowel Syndrome ("IBS").

 

The TrellusElevate™ platform is the Company's proprietary connected health
platform that incorporates the GRITT™ methodology and learnings on
resilience from clinical research and practice conducted at the Mount Sinai
IBD Center for more than five years. This proprietary, resilience-driven
methodology has been scientifically validated to demonstrate meaningful
improvements in patient outcomes, 71% reduction in Emergency Department
(A&E) visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for significant cost
savings for healthcare payers. IBD patients treated using the methodology also
experienced a 49% reduction in required opioid use and a 73% reduction in
corticosteroid use 12 months following program completion (source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258) ).

 

The Company was founded by Mount Sinai faculty members Dr. Marla C. Dubinsky,
MD and Dr. Laurie Keefer, PhD, both with decades of combined experience in IBD
and psychogastroenterology, respectively. Trellus Health's patent-pending
GRITT™ resilience assessment and personalized treatment methodology was
developed and validated at the Mount Sinai Health System to build resilience
and wellness for improved outcomes at lower cost.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information on Trellus Health, visit:
www.trellushealth.com (http://www.trellushealth.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOASEMSUIEESEFI